Please select the eligibility criteria that correspond to the clinical trial below.
Title: Dexamethasone for Cardiac Surgery Trial
Brief Summary: This is a multicenter, randomized, double-blind trial, comparing clinical outcomes after the administration of high-dose dexamethasone versus placebo in patients undergoing heart surgery with the use of cardiopulmonary bypass. The primary endpoint is the occurrence of major complications (including all-cause mortality, myocardial infarction, stroke, renal failure, and prolonged mechanical ventilation) in the first 30 days after surgery.


Options:
A: Inclusion Criteria:

* Severe community-acquired pneumonia Fine V
* CRP \>=15 mg/100 mL

Exclusion Criteria:

* Major contraindications for corticosteroids, such as uncontrolled diabetes, immunosuppression
* Previous glucocorticoid treatment during the previous month
* Documented extrapulmonary infection
* Previous hospitalization in the previous month
B: Inclusion Criteria:

* All types of cardiac surgery in which cardiopulmonary bypass is used

Exclusion Criteria:

* Age under 18 years
* Life-expectancy \< 6 months
* Emergency operations
* Re-operations within the same admission
C: Inclusion Criteria:

MUST HAVE:

General Anesthesia with volatile anesthetic

PATIENT CHARACTERISTICS

Major Criteria (any 1 of the following:)

1. Medications - anticonvulsants, abuse of opiates, benzodiazepines, cocaine
2. EF\<40%
3. Prior history of awareness (recall)
4. History of difficult intubation or anticipated difficult intubation
5. ASA IV or V status
6. Aortic stenosis
7. End stage lung disease
8. Marginal exercise tolerance not secondary to musculoskeletal dysfunction
9. Pulmonary hypertension
10. Daily alcohol consumption

Minor Criteria (any 2 of the following)

1. Beta blockers
2. COPD
3. Moderate exercise tolerance not secondary to musculoskeletal dysfunction
4. Smokes ≥2 packs per day
5. Morbid obesity BMI\>30 -

Exclusion Criteria:

1. Surgical procedure that prevents the use of the BIS (e.g surgery of forehead)
2. Patient positioning prevents use of the BIS
3. Surgery with wake-up test.
4. Less than 18 years of age
5. Vulnerable populations, such as those with dementia and those unable to provide informed consent.
6. Stroke with residual neurological deficits
D: Inclusion Criteria:

* Patients aged 70 years or over;
* The patient is at increased risk for developing in-hospital delirium on admission according to one or more positive answers on the VMS delirium-risk questions;
* The patient and/or proxy is able to provide written informed consent;
* The patient and/or proxy speaks either Dutch or English;
* The patient is admitted to the hospital for a general medicine or surgical specialty.

Exclusion Criteria:

* Patients presenting in the ED with delirium according to the DSM-IV criteria;
* Patients with clinically significant (cardiac) disorders: QTc interval prolongation (QTc ≥500ms), recent acute myocardial infarction, uncompensated heart failure (working diagnosis), acute coronary syndrome (ACS), arrhythmias treated with class IA and III antiarrhythmic medicinal products, history of ventricular arrhythmia, history of torsades, clinically significant bradycardia, second or third degree heart block, uncorrected hypokalaemia (potassium level 3.0 or lower);
* Patients with vascular dementia;
* Patients with Lewy Body dementia;
* Patients with Parkinson dementia;
* Patients with (a history of) hypokinetic movement disorders;
* Patients with (a history of) malignant neuroleptic syndrome;
* Patients with (a history of) serotonergic syndrome;
* Patients with (a history of) central anticholinergic syndrome;
* Patients who will be admitted to the oncology ward;
* Patients previously enrolled in the HARPOON study, or in other medical- or drug studies;
* Patients using QT prolonging drugs and/or medications of which concomitant use with haloperidol is contraindicated (clinically relevant drug interactions, 1st degree, listed in the appendix of the study protocol);
* Epilepsy;
* Substance abuse and dependence (DSM-IV criteria)
* Patients who are not able to take the study medication according to protocol (amendment)

Answer: B